Cargando…

Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis

PURPOSE: Wrist fractures are common, contribute significantly to morbidity in women with postmenopausal osteoporosis, and occur predominantly at the ultradistal radius, a site rich in trabecular bone. This exploratory analysis of the phase 3 ACTIVE study evaluated effects of abaloparatide versus pla...

Descripción completa

Detalles Bibliográficos
Autores principales: Watts, N.B., Hattersley, G., Fitzpatrick, L.A., Wang, Y., Williams, G.C., Miller, P.D., Cosman, F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546661/
https://www.ncbi.nlm.nih.gov/pubmed/30899994
http://dx.doi.org/10.1007/s00198-019-04890-2
_version_ 1783423547882864640
author Watts, N.B.
Hattersley, G.
Fitzpatrick, L.A.
Wang, Y.
Williams, G.C.
Miller, P.D.
Cosman, F.
author_facet Watts, N.B.
Hattersley, G.
Fitzpatrick, L.A.
Wang, Y.
Williams, G.C.
Miller, P.D.
Cosman, F.
author_sort Watts, N.B.
collection PubMed
description PURPOSE: Wrist fractures are common, contribute significantly to morbidity in women with postmenopausal osteoporosis, and occur predominantly at the ultradistal radius, a site rich in trabecular bone. This exploratory analysis of the phase 3 ACTIVE study evaluated effects of abaloparatide versus placebo and teriparatide on forearm bone mineral density (BMD) and risk of wrist fracture. METHODS: Forearm BMD was measured by dual energy X-ray absorptiometry in a subset of 982 women from ACTIVE, evenly distributed across the three treatment groups. Wrist fractures were ascertained in the total cohort (N = 2463). RESULTS: After 18 months, ultradistal radius BMD changes from baseline were 2.25 percentage points greater for abaloparatide compared with placebo (95% confidence interval (CI) 1.38, 3.12, p < 0.001) and 1.54 percentage points greater for abaloparatide compared with teriparatide (95% CI 0.64, 2.45, p < 0.001). At 18 months, 1/3 radius BMD losses (versus baseline) were similar for abaloparatide compared with placebo (−0.42; 95% CI −1.03, 0.20; p = 0.19) but losses with teriparatide exceeded those of placebo (−1.66%; 95% CI −2.27, −1.06; p < 0.001). The decline with abaloparatide was less than that seen with teriparatide (group difference 1.22%; 95% CI 0.57, 1.87; p < 0.001). The radius BMD findings, at both ultradistal and 1/3 sites, are consistent with the numerically lower incidence of wrist fractures observed in women treated with abaloparatide compared with teriparatide (HR = 0.43; 95% CI 0.18, 1.03; p = 0.052) and placebo (HR = 0.49, 95% CI 0.20, 1.19, p = 0.11). CONCLUSIONS: Compared with teriparatide, abaloparatide increased BMD at the ultradistal radius (primarily trabecular bone) and decreased BMD to a lesser extent at the 1/3 radius (primarily cortical bone), likely contributing to the numerically lower wrist fracture incidence observed with abaloparatide. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-019-04890-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6546661
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-65466612019-06-19 Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis Watts, N.B. Hattersley, G. Fitzpatrick, L.A. Wang, Y. Williams, G.C. Miller, P.D. Cosman, F. Osteoporos Int Original Article PURPOSE: Wrist fractures are common, contribute significantly to morbidity in women with postmenopausal osteoporosis, and occur predominantly at the ultradistal radius, a site rich in trabecular bone. This exploratory analysis of the phase 3 ACTIVE study evaluated effects of abaloparatide versus placebo and teriparatide on forearm bone mineral density (BMD) and risk of wrist fracture. METHODS: Forearm BMD was measured by dual energy X-ray absorptiometry in a subset of 982 women from ACTIVE, evenly distributed across the three treatment groups. Wrist fractures were ascertained in the total cohort (N = 2463). RESULTS: After 18 months, ultradistal radius BMD changes from baseline were 2.25 percentage points greater for abaloparatide compared with placebo (95% confidence interval (CI) 1.38, 3.12, p < 0.001) and 1.54 percentage points greater for abaloparatide compared with teriparatide (95% CI 0.64, 2.45, p < 0.001). At 18 months, 1/3 radius BMD losses (versus baseline) were similar for abaloparatide compared with placebo (−0.42; 95% CI −1.03, 0.20; p = 0.19) but losses with teriparatide exceeded those of placebo (−1.66%; 95% CI −2.27, −1.06; p < 0.001). The decline with abaloparatide was less than that seen with teriparatide (group difference 1.22%; 95% CI 0.57, 1.87; p < 0.001). The radius BMD findings, at both ultradistal and 1/3 sites, are consistent with the numerically lower incidence of wrist fractures observed in women treated with abaloparatide compared with teriparatide (HR = 0.43; 95% CI 0.18, 1.03; p = 0.052) and placebo (HR = 0.49, 95% CI 0.20, 1.19, p = 0.11). CONCLUSIONS: Compared with teriparatide, abaloparatide increased BMD at the ultradistal radius (primarily trabecular bone) and decreased BMD to a lesser extent at the 1/3 radius (primarily cortical bone), likely contributing to the numerically lower wrist fracture incidence observed with abaloparatide. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00198-019-04890-2) contains supplementary material, which is available to authorized users. Springer London 2019-03-21 2019 /pmc/articles/PMC6546661/ /pubmed/30899994 http://dx.doi.org/10.1007/s00198-019-04890-2 Text en © The Author(s) 2019 OpenAccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Watts, N.B.
Hattersley, G.
Fitzpatrick, L.A.
Wang, Y.
Williams, G.C.
Miller, P.D.
Cosman, F.
Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
title Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
title_full Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
title_fullStr Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
title_full_unstemmed Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
title_short Abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
title_sort abaloparatide effect on forearm bone mineral density and wrist fracture risk in postmenopausal women with osteoporosis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546661/
https://www.ncbi.nlm.nih.gov/pubmed/30899994
http://dx.doi.org/10.1007/s00198-019-04890-2
work_keys_str_mv AT wattsnb abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis
AT hattersleyg abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis
AT fitzpatrickla abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis
AT wangy abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis
AT williamsgc abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis
AT millerpd abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis
AT cosmanf abaloparatideeffectonforearmbonemineraldensityandwristfractureriskinpostmenopausalwomenwithosteoporosis